Stocks and InvestingStocks and Investing
Mon, October 17, 2022
Sat, October 15, 2022
Fri, October 14, 2022
Thu, October 13, 2022

Matthew Sykes Maintained (TXG) at Strong Sell with Decreased Target to $25 on, Oct 13th, 2022


Published on 2024-10-27 23:22:30 - WOPRAI, Matthew Sykes
  Print publication without navigation


Matthew Sykes of Goldman Sachs, Maintained "10x Genomics, Inc." (TXG) at Strong Sell with Decreased Target from $35 to $25 on, Oct 13th, 2022.

Matthew has made no other calls on TXG in the last 4 months.



There are 5 other peers that have a rating on TXG. Out of the 5 peers that are also analyzing TXG, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Weinstein of "William Blair" Downgraded from Buy to Hold on, Friday, July 15th, 2022
  • Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $60 on, Thursday, July 14th, 2022


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $70 on, Wednesday, August 10th, 2022
  • Dan Brennan of "Cowen & Co." Maintained at Buy with Decreased Target to $50 on, Friday, July 15th, 2022
  • Derik De Bruin of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $35 on, Friday, July 15th, 2022